Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Comfortable interest coverage of 8.2x
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ2.17 K Cr | β | βΉ157.00 Cr | β | β | 12.5% | -4.1% | 10.6% |
| Mar 2024 | βΉ2.27 K Cr | β | βΉ142.00 Cr | β | β | 12.1% | -9.2% | -7.2% |
| Mar 2023 | βΉ2.50 K Cr | β | βΉ153.00 Cr | β | β | 13.7% | 11.0% | -21.5% |
| Mar 2022 | βΉ2.25 K Cr | β | βΉ195.00 Cr | β | β | 20.0% | 17.5% | -24.4% |
| Mar 2021 | βΉ1.92 K Cr | β | βΉ258.00 Cr | β | β | 30.0% | 17.1% | 89.7% |
| Mar 2020 | βΉ1.64 K Cr | β | βΉ136.00 Cr | β | β | 21.9% | 12.4% | 56.3% |
| Mar 2019 | βΉ1.45 K Cr | β | βΉ87.00 Cr | β | β | 16.8% | 27.5% | 19.2% |
| Mar 2018 | βΉ1.14 K Cr | β | βΉ73.00 Cr | β | β | 16.8% | 4.7% | -2.7% |
| Mar 2017 | βΉ1.09 K Cr | β | βΉ75.00 Cr | β | β | 19.4% | 1.2% | 13.6% |
| Mar 2016 | βΉ1.08 K Cr | β | βΉ66.00 Cr | β | β | 18.9% | -1.0% | -15.4% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,237 |
| Total Expenses | 1,949 |
| EBIT / Operating Profit | 288 |
| OPM % | 13% |
| Other Income | 14 |
| Finance Costs | 28 |
| Depreciation & Amortisation | 50 |
| Profit Before Tax | 224 |
| Tax % | - |
| Net Profit / PAT | 190 |
| EPS (βΉ) | 20.87 |
| Dividend Payout % | - |
Peer Comparison
Materials sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Aarti Drugs Limitedthis co. | βΉ3.60 K Cr | βΉ2.17 K Cr | 18.90 | 2.68 | 14.06 | -4.1% |
| UltraTech Cement Ltd | βΉ3.55 L Cr | βΉ71.89 K Cr | 48.60 | 5.02 | 27.23 | 4.7% |
| JSW Steel Limited | βΉ2.88 L Cr | βΉ1.28 L Cr | 38.00 | 3.45 | 14.23 | -5.5% |
| Asian Paints Ltd. | βΉ2.77 L Cr | βΉ29.55 K Cr | 69.60 | 14.50 | 35.04 | -5.4% |
| Hindustan Zinc Ltd. | βΉ2.66 L Cr | βΉ33.97 K Cr | 25.50 | 19.57 | 18.58 | 17.4% |
| Coal India Limited | βΉ2.64 L Cr | βΉ1.59 K Cr | 12.40 | 13.24 | 16.33 | 5.1% |
| Vedanta Limited | βΉ2.49 L Cr | βΉ74.30 K Cr | 26.50 | 3.37 | 12.82 | 5.0% |
| Industry Average | β | βΉ10.75 K Cr | 47.54 | 5.23 | 30.19 | 121.8% |